Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey

BACKGROUND: Optimal use of bone-modifying agent (BMA) therapy in patients with bone metastases from breast and castrate-resistant prostate cancer (CRPC) is evolving. METHODS: Patients receiving BMA for bone metastases from breast or CRPC were surveyed. Information was collected on patient and diseas...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Support Care Cancer
Main Authors: Alzahrani, Mashari, Clemons, Mark, Sienkiewicz, Marta, Shrem, Noa Shani, McGee, Sharon F., Vandermeer, Lisa, Sehdev, Sandeep, Savard, Marie France, Awan, Arif, Canil, Christina, Hutton, Brian, Pond, Gregory, Saunders, Deanna, Ng, Terry
פורמט: Artigo
שפה:Inglês
יצא לאור: Springer Berlin Heidelberg 2021
נושאים:
Original Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC8140584/
https://ncbi.nlm.nih.gov/pubmed/34023950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00520-021-06238-1
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים